Investor News

November 17, 2009 - Issue of Equity

Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces that it has issued 259,200 new ordinary shares of 0.1p each ("New Ordinary Shares") pursuant to the exercise of options.

The issue of the New Ordinary Shares is subject to the New Ordinary Shares being admitted to trading on AIM, application for which has been made. Trading in the New Ordinary Shares, which will rank pari passu in all respects with the existing ordinary shares, is expected to commence on 23 November 2009. Following the issue the total number of ordinary shares in issue will be 178,697,988.

For further information:
Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer

Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com